Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.
2.
3.

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).

Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN.

Clin Chem. 2009 Mar;55(3):473-80. doi: 10.1373/clinchem.2008.111401. Epub 2009 Jan 15.

4.

Influence of triglyceride concentration on the relationship between lipoprotein cholesterol and apolipoprotein B and A-I levels.

Leroux G, Lemieux I, Lamarche B, Cantin B, Dagenais GR, Lupien PJ, Després JP.

Metabolism. 2000 Jan;49(1):53-61.

PMID:
10647064
5.
6.

The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus.

Toth PP, Simko RJ, Palli SR, Koselleck D, Quimbo RA, Cziraky MJ.

Cardiovasc Diabetol. 2012 Sep 14;11:109. doi: 10.1186/1475-2840-11-109.

8.

Establishing cut-off values for apolipoprotein B and non-HDL-C according to LDL-C values in a South European population.

Martinez-Hervas S, Real JT, Priego MA, Carratalá A, Sniderman AD, Carmena R, Ascaso JF.

Int J Clin Pract. 2013 Jan;67(1):81-8. doi: 10.1111/j.1742-1241.2012.02998.x.

PMID:
23241052
9.

Apolipoprotein B assessment for evaluating lipid goals.

Tekiner E, Oguz A, Uzunlulu M, Tekiner F.

Acta Cardiol. 2011 Aug;66(4):433-8.

PMID:
21894798
10.

Discordance between lipid markers used for predicting cardiovascular risk in patients with type 2 diabetes.

Modi KD, Chandwani R, Ahmed I, Kumar KV.

Diabetes Metab Syndr. 2016 Jan-Mar;10(1 Suppl 1):S99-S102. doi: 10.1016/j.dsx.2015.10.002. Epub 2015 Oct 24.

PMID:
26589777
11.

Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.

Kappelle PJ, Zwang L, Huisman MV, Banga JD, Sluiter WJ, Dallinga-Thie GM, Dullaart RP.

Expert Opin Ther Targets. 2009 Jul;13(7):743-51. doi: 10.1517/14728220903023866.

PMID:
19505224
12.

Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients.

Wägner AM, Pérez A, Calvo F, Bonet R, Castellví A, Ordóñez J.

Diabetes Care. 1999 May;22(5):812-7.

14.

Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial).

Grundy SM, Vega GL, Tomassini JE, Tershakovec AM.

Am J Cardiol. 2011 Jul 1;108(1):40-6. doi: 10.1016/j.amjcard.2011.03.003. Epub 2011 May 10.

PMID:
21565322
15.
16.

Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients.

Wägner AM, Pérez A, Zapico E, Ordóñez-Llanos J.

Diabetes Care. 2003 Jul;26(7):2048-51.

PMID:
12832311
17.

The pattern of dyslipidemia among urban African-Americans with type 2 diabetes.

Cook CB, Erdman DM, Ryan GJ, Greenlund KJ, Giles WH, Gallina DL, El-Kebbi IM, Ziemer DC, Ernst KL, Dunbar VG, Phillips LS.

Diabetes Care. 2000 Mar;23(3):319-24.

18.

The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.

Jimenez JG, Rosen JB, Pirags V, Massaad R, Hanson ME, Brudi P, Triscari J.

Diabetes Obes Metab. 2013 Jun;15(6):513-22. doi: 10.1111/dom.12059. Epub 2013 Jan 25.

PMID:
23279632
20.

Apolipoprotein measurements: is more widespread use clinically indicated?

Davidson MH.

Clin Cardiol. 2009 Sep;32(9):482-6. doi: 10.1002/clc.20559. Review.

Supplemental Content

Support Center